Effect of Lantus and Apidra in Patients With Acute ST Elevation Myocardial Infarction

Stopped early · Phase 3

Conditions studied: AMI

In brief

Primary objective: To demonstrate that in hyperglycemic subjects with anterior STEMI (ST Elevation Myocardial Infarction) undergoing Percutaneous Coronary Intervention (PCI), tight glycemic control using insulin glulisine and insulin glargine, i.e. Intensive Insulin Therapy (IIT), results in reducing infarct size at day 60 versus (vs) Standard Glycemic Care (SGC). Secondary objectives: To demonstrate that tight glycemic control using insulin glulisine and insulin glargine reduces markers of inflammation and improves Left Ventricular (LV) function and Cardio-Vascular (CV) outcomes from baseline values, in hyperglycemic subjects with STEMI undergoing Percutaneous Coronary Intervention (PCI).

Key facts

Study ID

NCT00670228

Run by

Sanofi

People needed

34

Starts

2008-04-01

Expected to finish

2009-11-01

Last updated by the study team

2011-02-11

Who can join

Age: 35 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men or women = or > 35 years of age presenting to the hospital with hyperglycemia (plasma glucose >140 mg/dL) and Primary Anterior wall ST-Elevation Myocardial Infarction (AW STEMI)
• No history of illicit drug abuse in past year
• A minimum of 30 minutes but < or = 6 hours of continuous pain/symptoms immediately prior to presentation
• Subjects who will undergo primary percutaneous coronary intervention (PCI)
• At least 2 contiguous precordial leads demonstrating at least 2 mm of ST-segment elevation consistent with anterior wall MI
• Signed informed consent and HIPAA documentation (US only) prior to participation in the study
• Subjects ability and willingness to adhere to and be compliant with study protocol

You may not qualify if…

• A prior history of Myocardial Infarction (MI)
• Subjects who have received any thrombolytic therapy during the current hospital admission
• Severe Heart Failure or cardiogenic shock (Killip class 3 or 4) by history or present at the time of screening
• Subjects with a plasma glucose >400 mg/dL or diabetic ketoacidosis (DKA)
• History of Type 1 diabetes
• Active bleeding
• Active malignancy, chronic or other medical conditions likely to result in death over the next one year
• Recent hypotension requiring inotropic support in the past 30 days
• Participation in another clinical research study in the past 30 days
• Pregnant or lactating women (women of childbearing potential must have a negative pregnancy test at study entry and a medically approved contraception method)
• Unwilling to give informed consent
• Subjects directly involved in the conduct of the study
• Known hypersensitivity to insulin glargine or glulisine
• Contraindication to MRI: a)Intracranial aneurysm clips (Unless the investigator is certain that it is made of non-ferromagnetic material such as titanium)b)Intra-orbital metal fragments c)Any electrically, magnetically or mechanically activated implants (including cardiac pacemakers, biostimulators, neurostimulators, cochlear implants, and hearing aids) d)Warning about Gadolinium-based contrast agents (GBCAs) Exposure to GBCAs increases the risk for nephrogenic systemic fibrosis (NSF). Therefore the following subjects should be excluded from the trial based on a history and/or laboratory tests:
• acute or chronic severe renal insufficiency (glomerular filtration rate <30 mL/min/1.73m2), as calculated by the MDRD (Modification of diet in Renal Disease) equation, or
• acute renal insufficiency of any severity
• Subjects with blood pressure > or = to 200/110 mmHg at time of randomization
• Subjects with a high degree of non-transient AV (Atrio-Ventricular) block
• The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

• Sanofi-Aventis Administrative Office — Bridgewater, New Jersey, United States
• Sanofi-Aventis Administrative Office — Buenos Aires, Argentina
• Sanofi-Aventis Administrative Office — São Paulo, Brazil
• Sanofi-Aventis Administrative Office — Laval, Canada
• Sanofi-Aventis Administrative Office — Col. Coyoacan, Mexico

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.